Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome

被引:26
作者
Franchini, Massimo
Zaffanello, Marco
Veneri, Dino
机构
[1] Osped Policlin, Serv Immunoematol & Trasfus, I-37134 Verona, Italy
[2] Univ Verona, Pediat Clin, I-37100 Verona, Italy
[3] Univ Verona, Dipartimento Med Sperimentale & Clin, Div Ematol, I-37100 Verona, Italy
关键词
D O I
10.1016/j.thromres.2005.07.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The thrombotic microangiopathies are microvascular occlusive disorders characterized by hemolytic anemia caused by fragmentation of erythrocytes and thrombocytopenia due to increased platelet aggregation and thrombus formation, eventually leading to disturbed microcirculation with reduced organ perfusion. Depending on whether brain or renal lesions prevail, two different entities have been described: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). However, not rarely the clinical distinctions between these two conditions remain questionable. Recent studies have contributed greatly to our current understanding of the molecular mechanisms leading to TTP and HUS. In this review, we briefly focus on the most important advances in the pathophysiology, diagnosis and treatment of these two thrombotic microangiopathies. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:177 / 184
页数:8
相关论文
共 100 条
[11]  
CUTTNER J, 1980, BLOOD, V56, P302
[12]   Response to plasma exchange and steroids as combined therapy for patients with thrombotic thrombocytopenic purpura [J].
de la Rubia, J ;
López, A ;
Arriaga, F ;
Cid, AR ;
Vicente, AI ;
Marty, ML ;
Sanz, MA .
ACTA HAEMATOLOGICA, 1999, 102 (01) :12-16
[13]   HEMOLYTIC UREMIC SYNDROME - THEN AND NOW [J].
DRUMMOND, KN .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (02) :116-118
[14]   Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak [J].
Dundas, S ;
Murphy, J ;
Soutar, RL ;
Jones, GA ;
Hutchinson, SJ ;
Todd, WTA .
LANCET, 1999, 354 (9187) :1327-1330
[15]   Plasma therapy in thrombotic thrombocytopenic purpura:: Review of the literature and the bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency [J].
Fontana, S ;
Hovinga, JAK ;
Studt, JD ;
Alberio, L ;
Lämmle, B ;
Taleghani, BM .
SEMINARS IN HEMATOLOGY, 2004, 41 (01) :48-59
[16]   Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family [J].
Fujikawa, K ;
Suzuki, H ;
McMullen, B ;
Chung, D .
BLOOD, 2001, 98 (06) :1662-1666
[17]   Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura -: new insights into underlying biochemical mechanisms [J].
Furlan, M ;
Lämmle, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (08) :1112-1114
[18]   Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura [J].
Furlan, M ;
Robles, R ;
Solenthaler, M ;
Wassmer, M ;
Sandoz, P ;
Lammle, B .
BLOOD, 1997, 89 (09) :3097-3103
[19]   Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura [J].
Furlan, M ;
Robles, R ;
Solenthaler, M ;
Lämmle, B .
BLOOD, 1998, 91 (08) :2839-2846
[20]   Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [J].
Furlan, M ;
Robles, R ;
Galbusera, M ;
Remuzzi, G ;
Kyrle, PA ;
Brenner, B ;
Krause, M ;
Scharrer, I ;
Aumann, V ;
Mittler, U ;
Solenthaler, M ;
Lämmle, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1578-1584